Program
peginterferon alfa-2b
Also written as “Peginterferon alfa-2b”, “peginterferon alfa-2b (SCH 54031)” and “PEG-Intron”.
Its studies are mostly in Hepatitis C, Chronic · Hepatitis C · Hepatitis B, Chronic · Melanoma · Hepatitis B, led by 4 companies.
Drug pagePeginterferon alfa-2b: every studyAll 139 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 450 open or running | phase 4since Nov 15, 2005 | Mar 29, 2000 | none ahead |
| Tanabe Pharma | 30 open or running | phase 3since Nov 2, 2011 | Feb 24, 2008 | none ahead |
| Xiamen Amoytop Biotechits history only | 32 open or running | phase 3since Apr 12, 2021 | Apr 12, 2021 | May 31, 2029NCT06707922 |
| FGK Clinical Researchits history only | 10 open or running | phase 4since Jul 11, 2006 | Jul 11, 2006 | none ahead |
Also a collaborator on its studies: Vertex Pharmaceuticals, Integrated Therapeutics Group, Johnson & Johnson and ViroPharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tanabe Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2008First study: phase 1 study in Hepatitis CFirst studyNCT00630058 · 20 enrolled · Japan
- Nov 2, 20112 phase 3 studies in Hepatitis C, ChronicNCT01468584, NCT01466192
TargetBeta
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| peginterferon alfa-2arule | Hoffmann-La Roche | phase 4 | 100 |
| Interferon beta-1arule | Biogen | phase 4 | 60 |
Studies
All 3 Tanabe Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01468584Hepatitis C, Chronic · Japan | 3 | Completed | Sep 2013 | 10 |
| NCT01466192Hepatitis C, Chronic · Japan | 3 | Completed | Aug 2013 | 108 |
| NCT00630058Hepatitis C · Japan | 1 | Completed | Mar 2009 | 20 |
How it is read
Names in the registry
- “Peginterferon alfa-2b”, 10 entries
- “peginterferon alfa-2b (SCH 54031)”, 5 entries
- “PEG-Intron”, 4 entries
- “PegIntron (peginterferon alfa-2b)”, 4 entries
- “Peginterferon alfa-2b injection”, 3 entries
Conditions, from the studies’ own filings
- Hepatitis C, Chronic, 31 studies
- Hepatitis C, 6 studies
- Hepatitis B, Chronic, 4 studies
- Melanoma, 4 studies
- Hepatitis B, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.